Founder/Innovation Leader
Bioleap
Bioleap provides a Hybrid-AI platform for precision biosimulation in therapeutic development. This technology utilizes highly detailed mechanistic models to offer 100x more accurate predictions with 20-fold less data requirement than traditional AI or QSP methods. The platform accelerates preclinical research, optimizes dosing, and enhances patient stratification across the immunotherapy pipeline.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$390KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Bioleap provides a Hybrid-AI platform for precision biosimulation in therapeutic development. This technology utilizes highly detailed mechanistic models to offer 100x more accurate predictions with 20-fold less data requirement than traditional AI or QSP methods. The platform accelerates preclinical research, optimizes dosing, and enhances patient stratification across the immunotherapy pipeline.